APYX Stock Forecast & Price Target

Apyx Medical Corp has demonstrated a positive financial outlook with Surgical Aesthetics revenue projected to reach between $43.0 million and $45.0 million, marking a 14.0% year-over-year growth at the midpoint. The company has also raised its full-year revenue guidance to a range of $50.5 million to $52.5 million, primarily driven by improved execution and demand trends within its Surgical Aesthetics segment. Additionally, Apyx's revenue for the quarter was reported at $12.9 million, representing a 12% increase compared to the prior year, further supported by a 19% growth in Surgical Aesthetics revenue linked to the successful launch of the AYON product.

Apyx Medical Corp has encountered a downward revision in original equipment manufacturing (OEM) sales expectations, now projected at approximately $7.5 million, reflecting a decline from prior projections due to decreased sales volumes to existing customers. The company’s stock has experienced volatility since its peak in September 2021, hampered by the lingering effects of an FDA warning letter and increasing competitive pressures linked to the rising use of GLP-1 medications. Additionally, Apyx's financial position is weakening, as evidenced by a drop in cash and cash equivalents from $29.3 million in 2Q25 to $25.1 million in 3Q25, further exacerbated by challenges within its Surgical Aesthetics segment, which generates over 80% of its revenue.